Global MicroRNA Expression Profiling of High-Risk ER+ Breast Cancers from Patients Receiving Adjuvant Tamoxifen Mono-Therapy: A DBCG Study-Reference-Cited by-同舟云学术

Global MicroRNA Expression Profiling of High-Risk ER+ Breast Cancers from Patients Receiving Adjuvant Tamoxifen Mono-Therapy: A DBCG Study

Published:2012-05-18 Issue:5 Volume:7 Page:e36170
ISSN:1932-6203
Container-title:PLoS ONE
language:en
Short-container-title:PLoS ONE

Author:

Lyng Maria B.,Lænkholm Anne-Vibeke,Søkilde Rolf,Gravgaard Karina H.,Litman Thomas,Ditzel Henrik J.

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference32 articles.

1. Guidelines on endocrine therapy of breast cancer EUSOMA.;RW Blamey;Eur J Cancer,2002

2. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.;C Davies;Lancet,2011

3. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.;M Baum;Lancet,2002

4. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1–98.;AS Coates;J Clin Oncol,2007

5. BIG 1–98: A randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. SABCS, abstract 13: abstracts2view.com/sabcs/view.php?;HT Mouridsen;nu = SABCS08L_,2008

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dual-target inhibitors based on ERα: Novel therapeutic approaches for endocrine resistant breast cancer;European Journal of Medicinal Chemistry;2024-04

2. Biomarkers and Treatment Strategies for Breast Cancer Recurrence;Current Drug Targets;2023-11

3. miRNAs in the prognosis of triple-negative breast cancer: A review;Life Sciences;2023-11

4. Integrated analysis identified prognostic microRNAs in breast cancer;BMC Cancer;2022-11-12

5. Current therapeutics and treatment options in TNBC;Combinational Therapy in Triple Negative Breast Cancer;2022